DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 18-781/S-079

Eli Lilly and Company
Attention: Jeffrey L. Winn, D.D.S., R.Ph.
Associate Director
U.S. Regulatory Affairs
Lilly Corporate Center
Indianapolis, IN 46285

Dear Dr. Winn:

Please refer to your supplemental new drug application dated March 5, 2004, received March 8, 2004, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Humulin N (human insulin [rDNA origin] isophane suspension).

We acknowledge receipt of your submission dated August 4, 2004.

This "Changes Being Effected" supplemental new drug application provides for an additional language emphasizing a need to prime Humulin N Pen before using it.

We completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling for Humulin N Pen (text for the patient package insert, Pen User Manual, and carton labels).

Please submit the FPL electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format – NDAs*. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 18-781/S-079." Approval of this submission by FDA is not required before the labeling is used.

The electronic labeling rule published December 11, 2003, (68 FR 69009) requires submission of labeling content in electronic format effective June 8, 2004. For additional information, consult the following guidances for industry regarding electronic submissions: *Providing Regulatory Submissions in Electronic Format - NDAs* (January 1999) and *Providing Regulatory Submissions in Electronic Format – Content of Labeling* (February 2004). The guidances specify that

labeling to be submitted in *pdf* format. If formatted copies of all labeling pieces (i.e., package insert, patient package insert, container labels, and carton labels) are submitted electronically, labeling does not need to be submitted in paper.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Julie Rhee, Regulatory Project Manager, at (301) 827-6424.

Sincerely,

{See appended electronic signature page}

David G. Orloff, M.D.
Director
Division of Metabolic
and Endocrine Drug products, HFD-510
Office of Drug Evaluation II
Center for Drug Evaluation and Research

Enclosures: 1. INFORMATION FOR THE PATIENT for Humulin N Pen (2.0 PV 3682 AMP)
2. User Manual for Humulin N Pen (3.0 PV 3734 AMP)
3. Carton label for Humulin N Pen (A1.0 NL 2493 AMS)

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

David Orloff

9/3/04 04:34:38 PM